{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:40Z","timestamp":1786975720056,"version":"build-2736575974"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Isolated tumor cells (ITCs) are the histopathological finding of small clusters of cancer cells no greater than 0.2 mm in diameter in the regional lymph nodes. For endometrial cancer, the prognostic significance of ITCs is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess clinico-pathological characteristics and oncologic outcomes associated with ITCs in endometrial cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study using the National Cancer Database included patients with endometrial cancer who had primary hysterectomy and nodal evaluation from 2018 to 2020. Patients with microscopic and macroscopic nodal metastases and distant metastases were excluded. Data were analyzed from June to September 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Regional nodal status with ITCs (N0[i+] classification) or no nodal metastasis (N0 classification).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n (1) Clinical and tumor characteristics associated with ITCs, assessed with multivariable binary logistic regression model, and (2) overall survival (OS) associated with ITCs, evaluated by nonproportional hazard analysis with restricted mean survival time at 36 months.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 56\u202f527 patients were included, with a median (IQR) age of 64 (57-70) years. The majority had T1a lesion (37\u202f836 [66.9%]) and grade 1 or 2 endometrioid tumors (40\u202f589 [71.8%]). ITCs were seen in 1462 cases (2.6%). In a multivariable analysis, ITCs were associated with higher T classification, larger tumor size, lymphovascular space invasion (LVSI), and malignant peritoneal cytology. Of those tumor factors, LVSI had the largest association with ITCs (7.9% vs 1.4%; adjusted odds ratio [aOR], 4.37; 95% CI, 3.87-4.93), followed by T1b classification (5.3% vs 1.3%; aOR, 2.62; 95% CI, 2.30-2.99). At the cohort level, 24-month OS rates were 94.3% (95% CI, 92.4%-95.7%) for the ITC group and 96.1% (95% CI, 95.9%-96.3%) for the node-negative group, and the between-group difference in expected mean OS time at 36 months was 0.35 (SE, 0.19) months, but it was not statistically significant (\n P<\/jats:italic>\n \u2009=\u2009.06). There was a statistically significant difference in OS when the low-risk group (stage IA, grade 1-2 endometrioid tumors with no LVSI) was assessed per nodal status and adjuvant therapy use (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001): (1) among the cases treated with surgical therapy alone, 24-month OS rates were 95.9% (95% CI, 89.5%-98.5%) for the ITC group and 98.8% (95% CI, 98.6%-99.0%) for the node-negative group, and the between-group mean OS time difference at 36 months was 0.61 (SE, 0.43) months (\n P<\/jats:italic>\n \u2009=\u2009.16); and (2) among the cases with ITCs, adjuvant therapy (radiotherapy alone, systemic chemotherapy alone, or both) was associated with improved survival compared with no adjuvant therapy (24-month OS rates, 100% vs 95.9%; between-group mean OS time difference at 36 months, 0.95 [SE, 0.43] months;\n P<\/jats:italic>\n \u2009=\u2009.03).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with surgically staged endometrial cancer, the results of exploratory analysis suggested that presence of ITCs in the regional lymph node may be associated with OS in the low-risk group. While adjuvant therapy was associated with improved OS in the low-risk group with ITCs, careful interpretation is necessary given the favorable outcomes regardless of adjuvant therapy use. This hypothesis-generating observation in patients with low-risk endometrial cancer warrants further investigation, especially with prospective setting.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.0988","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:35:13Z","timestamp":1710761713000},"page":"e240988","source":"Crossref","is-referenced-by-count":16,"title":["Lymph Node Isolated Tumor Cells in Patients With Endometrial Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles"},{"name":"Norris Comprehensive Cancer Center, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica K.","family":"Neuman","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Klar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Freiburg Faculty of Medicine, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles"},{"name":"Norris Comprehensive Cancer Center, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"1","key":"zoi240068r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.v73.1","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10333","key":"zoi240068r2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer.","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"zoi240068r3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2018.02.021","article-title":"Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual.","volume":"150","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"zoi240068r5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ygyno.2021.02.017","article-title":"Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I\/II endometrioid endometrial cancer: to treat or not to treat?","volume":"161","author":"Backes","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi240068r6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ygyno.2021.06.031","article-title":"Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: an international multi-institutional study.","volume":"162","author":"Ghoniem","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"zoi240068r7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ygyno.2017.05.024","article-title":"Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter?","volume":"146","author":"Plante","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"zoi240068r8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1245\/s10434-015-5040-z","article-title":"Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma.","volume":"23","author":"St Clair","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"zoi240068r9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2022.02.015","article-title":"Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer.","volume":"165","author":"Matsuo","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi240068r10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma.","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"zoi240068r11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ygyno.2019.02.027","article-title":"Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells.","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"zoi240068r13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE Reporting Guidelines for Observational Studies.","volume":"156","author":"Ghaferi","year":"2021","journal-title":"JAMA Surg"},{"issue":"2","key":"zoi240068r14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.v162.2","article-title":"FIGO staging of endometrial cancer: 2023.","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"zoi240068r15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"zoi240068r16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/IGC.0b013e3182954da8","article-title":"Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.","volume":"23","author":"Kim","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"zoi240068r17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2010.08.030","article-title":"Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?","volume":"119","author":"Frimer","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"6","key":"zoi240068r18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jso.v112.6","article-title":"Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer.","volume":"112","author":"Matsuo","year":"2015","journal-title":"J Surg Oncol"},{"issue":"13","key":"zoi240068r19","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer\u2014a pooled analysis of PORTEC 1 and 2 trials.","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"zoi240068r20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/AOG.0000000000004733","article-title":"Utilization and outcomes of sentinel lymph node biopsy for early endometrial cancer.","volume":"139","author":"Matsuo","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi240068r21","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1245\/s10434-023-13310-z","article-title":"Cancer stage-shifting with sentinel lymph node biopsy in low-grade endometrial cancer.","volume":"30","author":"Matsuo","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"zoi240068r22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2020.03.031","article-title":"Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.","volume":"133","author":"Matsuo","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7447","key":"zoi240068r23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma.","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"zoi240068r4","unstructured":"National Comprehensive Cancer Network. Uterine neoplasms. Accessed August 26, 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1473"},{"key":"zoi240068r12","unstructured":"American College of Surgeons. National Cancer Database. Accessed August 26, 2023. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2816410\/matsuo_2024_oi_240068_1710514371.83738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:35:16Z","timestamp":1710761716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2816410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0988","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}